Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis
Latest Information Update: 26 Sep 2024
At a glance
- Drugs RNS 60 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Revalesio
- 09 Sep 2024 Planned End Date changed from 1 Nov 2026 to 1 Nov 2027.
- 09 Sep 2024 Planned primary completion date changed from 1 Nov 2026 to 1 Nov 2027.
- 09 Sep 2024 Planned initiation date changed from 1 Oct 2024 to 1 Oct 2025.